ATE273285T1 - Neue guanidin-derivate als zelladhäsion- inhibitoren - Google Patents

Neue guanidin-derivate als zelladhäsion- inhibitoren

Info

Publication number
ATE273285T1
ATE273285T1 AT00905022T AT00905022T ATE273285T1 AT E273285 T1 ATE273285 T1 AT E273285T1 AT 00905022 T AT00905022 T AT 00905022T AT 00905022 T AT00905022 T AT 00905022T AT E273285 T1 ATE273285 T1 AT E273285T1
Authority
AT
Austria
Prior art keywords
cell adhesion
formula
compounds
guanidine derivatives
adhesion inhibitors
Prior art date
Application number
AT00905022T
Other languages
German (de)
English (en)
Inventor
Anuschirwan Peyman
Jochen Knolle
Karl-Heinz Scheunemann
David William Will
Denis Carniato
Jean-Francois Gourvest
Thomas Gadek
Sarah Catherine Bodary
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE273285T1 publication Critical patent/ATE273285T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/16Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT00905022T 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren ATE273285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99102916A EP1028114A1 (en) 1999-02-13 1999-02-13 Novel guanidine derivatives as inhibitors of cell adhesion
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
ATE273285T1 true ATE273285T1 (de) 2004-08-15

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905022T ATE273285T1 (de) 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren

Country Status (11)

Country Link
US (1) US6340679B1 (https=)
EP (2) EP1028114A1 (https=)
JP (1) JP4642242B2 (https=)
AT (1) ATE273285T1 (https=)
AU (1) AU768206B2 (https=)
CA (1) CA2371789C (https=)
DE (1) DE60012890T2 (https=)
ES (1) ES2225086T3 (https=)
IL (1) IL144725A0 (https=)
MX (1) MXPA01008072A (https=)
WO (1) WO2000047564A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CZ2002518A3 (cs) 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
ATE308981T1 (de) 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
EP0907637A1 (de) * 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
YU47200A (sh) 1998-01-23 2002-11-15 Aventis Pharma Deutschland Gmbh. Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije

Also Published As

Publication number Publication date
EP1155003A1 (en) 2001-11-21
CA2371789C (en) 2009-04-14
AU768206B2 (en) 2003-12-04
EP1155003B1 (en) 2004-08-11
JP4642242B2 (ja) 2011-03-02
IL144725A0 (en) 2002-06-30
AU2669900A (en) 2000-08-29
MXPA01008072A (es) 2002-07-30
US6340679B1 (en) 2002-01-22
WO2000047564A1 (en) 2000-08-17
DE60012890D1 (de) 2004-09-16
EP1028114A1 (en) 2000-08-16
JP2002536438A (ja) 2002-10-29
CA2371789A1 (en) 2000-08-17
ES2225086T3 (es) 2005-03-16
DE60012890T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BR0212069A (pt) Agentes antidiabéticos orais
MY133246A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
AU2001277752A1 (en) Calcium receptor antagonists
PT1179342E (pt) Composicoes medicinais de libertacao imediata para utilizacao oral
ATE360018T1 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
ATE432934T1 (de) Neue guanidino derivate als zelladhäsionhemmer
AR030874A1 (es) Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso
TH65078A (th) อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล
ATE524442T1 (de) Antiproliferative wirkstoffe
TW200607498A (en) Agents for prevention or treatment of diseases associated with endothelial hyperproliferation
TH64558A (https=)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties